126 related articles for article (PubMed ID: 31480015)
1. Determinants of the growth hormone nadir during oral glucose tolerance test in adults.
Monaghan PJ; Trainer PJ
Eur J Endocrinol; 2019 Nov; 181(5):C17-C20. PubMed ID: 31480015
[No Abstract] [Full Text] [Related]
2. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.
Karavitaki N; Fernandez A; Fazal-Sanderson V; Wass JA
Clin Endocrinol (Oxf); 2009 Dec; 71(6):840-5. PubMed ID: 19320648
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly: are new tests needed?
Spada A
J Endocrinol Invest; 2003 Feb; 26(2):104-5. PubMed ID: 12739734
[No Abstract] [Full Text] [Related]
4. Pitfalls in the diagnosis of acromegaly.
Pokrajac-Simeunovic A; Trainer PJ
Horm Res; 2004; 62 Suppl 3():74-8. PubMed ID: 15539804
[TBL] [Abstract][Full Text] [Related]
5. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
[TBL] [Abstract][Full Text] [Related]
6. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly symptoms without pituitary adenoma in an adolescent.
Güven A; Ozgen T; Belet U; Aydin M
J Pediatr Endocrinol Metab; 2007 Aug; 20(8):945-9. PubMed ID: 17937067
[TBL] [Abstract][Full Text] [Related]
9. Limited utility of oral glucose tolerance test in biochemically active acromegaly.
Ribeiro-Oliveira A; Faje AT; Barkan AL
Eur J Endocrinol; 2011 Jan; 164(1):17-22. PubMed ID: 20926592
[TBL] [Abstract][Full Text] [Related]
10. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
11. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma.
Herlihy OM; Perros P
Diabetes Metab Res Rev; 2000; 16(3):211-6. PubMed ID: 10867721
[TBL] [Abstract][Full Text] [Related]
13. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.
Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J
Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207
[TBL] [Abstract][Full Text] [Related]
14. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.
Grottoli S; Razzore P; Gaia D; Gasperi M; Giusti M; Colao A; Ciccarelli E; Gasco V; Martino E; Ghigo E; Camanni F
J Endocrinol Invest; 2003 Feb; 26(2):123-7. PubMed ID: 12739738
[TBL] [Abstract][Full Text] [Related]
15. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
17. Should we still use glucose-suppressed growth hormone levels for the evaluation of acromegaly?
Colao A; Lombardi G
J Clin Endocrinol Metab; 2008 Apr; 93(4):1181-2. PubMed ID: 18390816
[No Abstract] [Full Text] [Related]
18. Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility.
Arafat AM; Müller L; Möhlig M; Mayr B; Kremenevskaya N; Pfeiffer AF; Buchfelder M; Schöfl C
Clin Endocrinol (Oxf); 2011 Nov; 75(5):685-91. PubMed ID: 21575028
[TBL] [Abstract][Full Text] [Related]
19. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
20. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
